Home › Funds › Hardman Johnston Global Advisors LLC › BSX

Hardman Johnston Global Advisors LLC position in BSX

BOSTON SCIENTIFIC CORP · Health Care

Hardman Johnston Global Advisors LLC reported holding 235,344 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$10.3M, representing 0.31% of its reported portfolio and ranking #42 among its reported holdings. Hardman Johnston Global Advisors LLC has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)235.34K sh
Reported value held$10.27M
Portfolio Weight0.31%
First reportedQ3 2023
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Hardman Johnston Global Advisors LLC's BSX position evolved

Hardman Johnston Global Advisors LLC first disclosed a stake in BSX in Q3 2023 at 650,130 shares (US$34.3M). The position peaked in Q1 2024 at 652,614 shares, worth US$44.7M. Across 13 filings, Hardman Johnston Global Advisors LLC increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 235,344 shares valued at US$10.3M — an increase of 66,984 shares quarter over quarter.. Notable position changes include a 46% trim in Q2 2024 (shares rose 9% over the following quarter), a 28% trim in Q3 2024 (shares rose 7% over the following quarter), a 40% increase in Q3 2026 (shares rose 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 650.13K $34.33M New
Q4 2023 674.94K $39.02M Add
Q1 2024 652.61K $44.70M Reduce
Q2 2024 354.54K $27.30M Reduce
Q3 2024 256.99K $21.54M Reduce
Q4 2024 326.90K $29.20M Add
Q1 2025 287.25K $28.98M Reduce
Q2 2025 233.50K $25.08M Reduce
Q3 2025 237.35K $23.17M Add
Q4 2025 228.26K $21.76M Reduce
Q1 2026 166.02K $10.42M Reduce
Q2 2026 168.36K $7.19M Add
Q3 2026 235.34K $10.27M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BSX and 13F data

BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 20 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.56B), MFS Investment Management (US$2.29B), Arrowstreet Capital (US$1.24B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BSX

All BSX fund holders →

FAQ

How long has Hardman Johnston Global Advisors LLC held BSX?

Hardman Johnston Global Advisors LLC has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Hardman Johnston Global Advisors LLC's current position in BSX?

As of Q3 2026, Hardman Johnston Global Advisors LLC holds 235.34K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $10.27M, representing 0.31% of its reported portfolio and ranking #42.

Has Hardman Johnston Global Advisors LLC been buying or selling BSX?

In the latest 13F filing (Q3 2026), Hardman Johnston Global Advisors LLC increased its position in BSX. The position peaked in Q1 2024 at 652.61K shares.

Which other funds hold BSX?

Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, MFS Investment Management, Arrowstreet Capital, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.